The largest database of trusted experimental protocols

Anti mr1 clone 26

Manufactured by BioLegend
Sourced in United States

Anti-MR1 (Clone 26.5) is a monoclonal antibody that binds to the MR1 protein. MR1 is a non-classical major histocompatibility complex (MHC) class I-like molecule that presents metabolite antigens to mucosal-associated invariant T (MAIT) cells. This antibody can be used to identify and study MR1-expressing cells.

Automatically generated - may contain errors

2 protocols using anti mr1 clone 26

1

Activation of human MAIT cells by 5-A-RU and MGO

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human whole leukocytes from anonymous healthy donors were isolated from apheresis cones from ARUP using RBC sedimentation with HetaSep (STEMCELL Technologies, Vancouver, British Columbia). Freshly isolated whole leukocytes were used fresh for in vitro culture.
Whole leukocytes were cultured with or without 5-A-RU (50 nM) and MGO (50 µM) in 200 µL RPMI complete media and incubated at 37 °C overnight. CD69, and eotaxin, granzyme A, and in MAIT cells and Eosinophils were analyzed using flow cytometry. To detect released cytokines in the medium, 25 µL of supernatant was analyzed using Cytokine 35-Plex Human Panel for the Luminex platform (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) on the Luminex MAGPIX. To block interactions activation of MAIT cell via MR1, anti-MR1 (Clone 26.5, Biolegend, San Diego, CA, USA) or an isotype control was used at 10 µg/ml.
+ Open protocol
+ Expand
2

MAIT Cell-Mediated Breast Cancer Cytotoxicity

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell preparations containing primary MAIT cells (CD161+ PBMCs or breast epithelial organoid cells) or in vitro-expanded MAIT cultures were added to wells containing E. coli-exposed or mock-treated MDA-MB-231 breast carcinoma cells. CD161+ PBMCs and in vitro-expanded MAIT cells were added at a 1:1 ratio to breast carcinoma cells, whereas the breast epithelial organoid cells (which are composed of both IELs and epithelial cells) were added at a 3:1 ratio. Where indicated, the following blocking antibodies were added to the cocultures: 20 μg/ml anti-MR1 (clone 26.5; BioLegend) or 5 μg/ml anti-NKG2D (1D11; BioLegend). The carcinoma and effector cells were coincubated at 37 °C for ~ 18 hours, then monensin (GolgiStop) or brefeldin A (GolgiPlug) was added to all cultures, and the cells were coincubated for an additional 6 hours. After ~ 24 hours of coincubation, the effector cells were resuspended using cold EDTA (500 mM) in PBS, washed, and analyzed by flow cytometry.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!